Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Open Biology|June 8, 2018
Cancer immunotherapy: broadening the scope of targetable tumoursJitske van den Bulk, Els Me Verdegaal, Noel Fcc de MirandaClinical Science (London, England : 1979)|January 5, 2021
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppressionJitske van den Bulk, Noel F C C de Miranda, Peter Ten DijkeOncotarget|January 26, 2017
Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancerErik J Blok, Jitske van den Bulk, N Geeske Dekker-Ensink, et al.Cell Reports Methods|July 22, 2026
Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4+ T cell helpYizhi Wang, Xin Lei, Tom de Wit, et al.Oncoimmunology|September 14, 2020
Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancerBrett J Hos, Marcel G M Camps, Jitske van den Bulk, et al.Cell Reports|October 12, 2022
Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITABrett J Hos, Elena Tondini, Marcel G M Camps, et al.Journal for Immunotherapy of Cancer|February 15, 2023
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burdenJitske van den Bulk, Manon van der Ploeg, Marieke E Ijsselsteijn, et al.Genome Medicine|January 1, 2020
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4Jitske van den Bulk, Els M E Verdegaal, Dina Ruano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2023
Neoantigen Targetability in Progressive Advanced MelanomaJitske van den Bulk, Els M E Verdegaal, Manon van der Ploeg, et al.Nature|January 11, 2023
γδ T cells are effectors of immunotherapy in cancers with HLA class I defectsNatasja L de Vries, Joris van de Haar, Vivien Veninga, et al.Pageof 2